Danirixin is a selective, and reversible CXCR2 antagonist, with IC 50 ?of?12.5 nM for CXCL8.
性状
Solid
IC50 & Target[1][2]
CXCL8-CXCR2 12.5 nM (IC50)
体外研究(In Vitro)
Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Miller BE, et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist?--in healthy adult subjects. BMC Pharmacol Toxicol. 2015 Jun 20;16:18.
溶解度数据
In Vitro: DMSO : 8 mg/mL (18.10 mM; Need ultrasonic and warming)配制储备液